

MedInvent, LLC announces issuance of new US patent 9,440,020

September 13, 2016, Medina, OH. MedInvent, LLC announced today the issuance of US Patent 9,440,020 Nasal Irrigator.

William Flickinger, CEO stated: "We continue to work to develop new and novel concepts in nasal drug delivery to meet the unmet needs of people suffering from chronic sinus conditions and other disorders where nasal drug delivery may improve their lives. The NasoNeb technology provides a high concentration of medication to be delivered throughout the nasal cavity, providing for improved coverage for locally active drugs and more surface area for systemically-absorbed drugs, offering a potential solution to pharmacologists facing the challenge of limited bioavailability common with traditional delivery devices. The ability of the NasoNeb to reliably reach the olfactory cleft provides a pathway to the CNS and lymphatic vessels draining the central nervous system."

The NasoNeb Nasal Nebulizer is available by prescription-only compounding pharmacies across the US and in select countries.

For more information, please visit the MedInvent, LLC website at www.nasoneb.com.

About MedInvent, LLC

MedInvent, LLC is a privately-held limited liability corporation established in 2008 with operations in Medina, OH. MedInvent develops and markets the NasoNeb Family of drug delivery systems for the topical delivery of medication to the nasal and paranasal sinus cavities. The NasoNeb Nasal Nebulizer is indicated for topical drug delivery to the nasal cavity for drugs formulated for inhalation.

Contact William Flickinger at 330-247-0921 for more information or visit our website at www.nasoneb.com

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, the effect of global credit and economic conditions on the ability and willingness of customers to purchase our systems, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risk. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.